Topical Arnica and Mucopolysaccharide Polysulfate on Postoperative Pain, Edema and Trismus
Impacted Third Molar Tooth
About this trial
This is an interventional supportive care trial for Impacted Third Molar Tooth focused on measuring impacted third molar, oral surgery, edema, trismus, pain, postoperative sequelae
Eligibility Criteria
Inclusion Criteria:
- Age between 16-68 years
- American Society of Anesthesiologists (ASA) Class 1 physiological status
- Consistent radiological and clinical data
- Volunteered to participate in the study
- Scale II" surgery difficulty according to Modified Parant Classification for mandibular impacted third molar removal, be free of pericoronitis and infection at operation time
Exclusion Criteria:
- Being out of age range
- Pregnancy or lactation
- Analgesic or antibiotic therapy history in last 14 days due to symptoms of related third molar
- Smoking cigarette
- Any pathology associated with impacted third molar
- Active complaints on preoperative examination on the day of surgery
- Immunosuppressed or diagnosed with malignancy
- Diagnosed chronic diseases such as; Diabetes mellitus (DM), hypertension, cerebrovascular event, psychiatric diseases, coagulopathies
- Autoimmune diseases
- Patients who could not attend regular follow-up visits
- Allergy to the medications prescribed or utilized in study protocol
- Inconsistent clinical and radiological data or missed follow-up
Sites / Locations
- Abant Izzet Baysal University
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Other
Postoperative topical arnica montana cream
Postoperative topical mucopolysaccharide polysulfate cream
Control group
In this arm, Arnica group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
In this arm, Mucopolysaccharide polysulfate group consisted of 20 patients who were treated with topical arnica in addition to standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.
In this arm control group consisted of 20 patients who were treated with only standard therapy (amoxicillin/clavulanic acid 500/125 mg twice a day and diclofenac potassium 50 mg twice a day) after mandibular impacted third molar surgery.